drugset / Trial / NCT06904196
Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
Non-randomizedParallel-groupSingle-blindTreatment
Summary
This study is conducted to evaluate the efficacy and safety of lenvatinib plus SIRT (LEN+SIRT) compared with lenvatinib (LEN) alone for patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE).
Timeline
- Start
- 2025-04-01
- Primary completion
- 2028-03-31
- Completion
- 2029-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lenvatinib | Small molecule | 8 mg | Oral |
| Comparator | Lenvatinib | Small molecule | 12 mg | Oral |